Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Azithromycin microspheres 2.0 single dose · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Azithromycin microspheres 2.0 single dose | DRUG | - |
Inclusion Criteria: * Male or female, 18 years age or older, for whom oral, outpatient therapy is indicated. * Diagnosis of CAP as manifested by at least 3 or more of the following: * cough, pleuritic chest pain, fever (temperature of \>37.8 C to \<40 C), auscultatory findings on pulmonary examinat...
Azithromycin microspheres 2.0 single dose is an investigational small molecule formulation of azithromycin developed by Pfizer, Inc. (NYSE: PFE) for the treatment of community-acquired pneumonia. It is a single-dose microsphere formulation designed to deliver the antibiotic in one administration. It is currently in Phase 3 clinical development.
Azithromycin microspheres 2.0 single dose is being developed for the treatment of community-acquired pneumonia. It is intended for patients with low risk community-acquired pneumonia, as studied in a Phase 3 trial. It is an investigational formulation and is not approved for commercial use.
Azithromycin microspheres 2.0 single dose is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical development program for this single-dose microsphere formulation of azithromycin.
Azithromycin microspheres 2.0 single dose is in Phase 3 clinical development. One Phase 3 trial has been completed, and there are currently no active trials. The drug remains investigational and has not been approved by the FDA for any indication.
Azithromycin microspheres 2.0 single dose has been studied in one completed Phase 3 trial, NCT00140023, titled Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia. The trial enrolled 47 patients in the Philippines and was an uncontrolled study in adults aged 18 years and older.